Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis

Leukemia

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis

Leuk Lymphoma

Alhajahjeh A, Beke KE, Grimshaw AA, Aguirre LE, Mina A, Podoltsev NA, Mendez L, Stahl M, Zeidan AM, Bewersdorf JP

doi: 10.1080/10428194.2026.2682397

Genitourinary Cancer

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis

Prostate Cancer Prostatic Dis

Saporita I, Calabrese M, Carfi FM, Mogavero A, Puglisi M, Treglia G, Vogl UM, Gillessen S, Pereira Mestre R, Pedrani M, Pecoraro G, Salfi G, Erhart CC, Lin HM, Tortola L, Di Maio M, Tucci M, Buttigliero C, Turco F

doi: 10.1038/s41391-026-01077-9

Leukemia

Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis

Haematologica

Chang YS, Lee YW, Liu CY, Othman J, Eckardt JN, Zhou Q, Tien FM, Lyu TW, Tsai XC, Lin CC, Chang H, Ko BS, Chou WC, Röllig C, Russell N, Dillon R, Hou HA

doi: 10.3324/haematol.2025.288081

Leukemia

Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis

Leuk Lymphoma

Huang YH, Liu FT, Wan CL, Wang ZJ, Liu YQ, Cao HY, Huang SM, Tan KW, Ge SS, Wang M, Liu MJ, Wang ZH, Lyu XY, Dai HP, Li Z, Xue SL

doi: 10.1080/10428194.2025.2566317

Leukemia

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy

Haematologica

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Zeidner JF, Olin RL, Smith CC, Schiller GJ, Curran EK, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF

doi: 10.3324/haematol.2025.288743

Genitourinary Cancer

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration

Lancet Oncol

Tang C, Sherry AD, Hwang H, Farris DP, Francolini G, Di Cataldo V, Livi L, Tran P, Corn PG, Aparicio A, Simontacchi G, Kiess AP, Wang JH, Fonteyne V, Bultijnck R, Phillips R, Deek MP, Olson R, Harrow S, Marvaso G, Lorubbio C, Jereczek-Fossa BA, Ludmir EB, Blanchard P, Warner A, Sun R, Palma DA, Ost P

doi: 10.1016/S1470-2045(25)00658-8

Lung, Respiratory and Thoracic Cancer

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes

Cancer Treat Rev

Marinelli D, Citarella F, Torchia A, Pannu S, Aijaz A, Sisca L, Russano M, Fujiwara Y, Takada K, Nassar AH, Banna GL, Ricciuti B, Brunetti L, Santo V, Passaro A, Saw SPL, Li MSC, Addeo A, Ferrara R, Di Maio M, Mountzios G, Santini D, Maugeri-Saccà M, Vincenzi B, Acker F, Reckamp KL, Cappuzzo F, Naqash AR, Cortellini A

doi: 10.1016/j.ctrv.2026.103159

Further Publications

Role of the perinatal experience on the risk of acute leukemia in childhood or adolescence: Systematic review and meta-analysis

Int J Cancer

Blanco-Lopez J, Kintossou AK, Manohar S, Iguacel I, Pisanu S, Almeida CCB, Steliarova-Foucher E, Sierens C, Gunter MJ, Ladas EJ, Barr RD, Van Herck K, Kozlakidis Z, Huybrechts I

doi: 10.1002/ijc.70256

Leukemia

Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients

Am J Hematol

Kumar S, Warraich M, Fatima M, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Saliba AN, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Foran J, Palmer J, Yi CA, Tefferi A, Gangat N

doi: 10.1002/ajh.70500

Related content

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis

Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis

Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes

Role of the perinatal experience on the risk of acute leukemia in childhood or adolescence: Systematic review and meta-analysis

Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients